BGPT: Create Tables: Cas9 vs Cas12 vs Cas13 readout modalities for animal pathogens

Explore by Goal

Quick Explanation Copied

Cas9 vs Cas12 vs Cas13 (animal-pathogen diagnostics): Cas12/Cas13 are commonly paired with collateral cleavage to drive fluorescence or lateral-flow (LFA/LFB) readouts, while Cas9 is frequently used for host/pathogen nucleic-acid processing (e.g., depletion) where the final signal comes from sequencing or downstream detection rather than collateral-cleavage reporters. Sources: animal-CRISPR diagnostic review () and Cas13/Cas12 example implementations (, ).

Long Explanation

Readout modalities for Cas9 vs Cas12 vs Cas13 in animal-pathogen CRISPR diagnostics

Evidence is limited to what your provided raw dataset explicitly states; the heatmap below encodes only modalities that are directly mentioned in those sources.

Heatmap evidence anchors: Animal diagnostic review (), Cas13 CARMEN fluorescence readout (), Cas12 fluorescence+LFA examples (, ), Cas9 sequencing-based pipeline (host depletion + ONT sequencing) ().

Cas9 vs Cas12 vs Cas13: what drives the signal (readout mechanism)

The “readout modality” is the observable output (fluorescence/LFA/etc.), while “signal-generation logic” clarifies whether the CRISPR system directly produces the reporter signal or primarily enables downstream detection.

Cas system	Common readout modalities (from provided sources)	Signal-generation logic (from provided sources)	Animal-pathogen context in provided sources
Cas9	Sequencing/amp downstream (after depletion)	Cas9 is used for host nucleic-acid depletion (DASH), changing the input composition so that downstream sequencing can detect pathogens at higher effective sensitivity.	Review covers Cas9/Cas12/Cas13 in animal infectious diagnostics; the provided Cas9 example is serum RNA sequencing with ONT and DASH.
Cas12 (e.g., Cas12a)	Fluorescence + Lateral-flow (LFB/LFA)	Cas12 collateral cleavage is leveraged to generate detectable reporter signals (fluorescent reporters and LFB strips are explicitly described in the provided Cas12 studies).	Examples include bacterial pathogens with clinical/field matrices (streptococcal throat/conjunctival samples; environmental Legionella water samples), aligned with the review’s framing of rapid point-of-need diagnostic readouts.
Cas13 (e.g., Cas13a)	Fluorescence (image-mapped)	Cas13 collateral cleavage enables fluorescence reporters to be read out from microfluidic droplets, with mapping to thousands of crRNA–target pairs in CARMEN.	Provided Cas13 data focuses on multiplexed viral detection in human samples (pathogen diagnostics relevant to One Health/animal-zoonotic risk); the animal diagnostic review generalizes Cas13 readout classes.

Table evidence: Cas9 sequencing via DASH (), Cas12a fluorescence+LFB (, ), Cas13 fluorescence in CARMEN (), and overall readout-category framing for animal pathogens ().

Modality “coverage” (binary, based on what’s explicitly in the provided papers)

Skeptical interpretation & known blind spots

Binary heatmap = evidence-limited. It only marks modalities explicitly mentioned in the provided sources; the lack of a modality in this dataset is not proof it is absent in real-world Cas9/12/13 diagnostics. ()
Cas9 often isn’t the “reporter” enzyme. In the provided Cas9 example (DASH), Cas9 acts on abundant host RNAs, and the final observation is sequencing-based. Other Cas9 diagnostic designs may use different readouts, but those are not evidenced in the provided Cas9 dataset excerpt. ()
Collateral cleavage ≠ universal performance. Even when fluorescence/LFA is available, real-world sensitivity/specificity depend on sample matrix, amplification strategy, crRNA design breadth, and device/instrument constraints. The provided sources include both performance and limitations (e.g., crRNA coverage dependence and specialized microfluidics for CARMEN). (, )

Feedback:

Updated: April 30, 2026

Top Data Sources Export MCP

1. The study introduces CARMEN–Cas13, a massively multiplexed CRISPR-based nucleic acid detection platform that uses microdroplet microwell arrays to test thousands of crRNA–target pairs in parallel, enabling comprehensive detection and subtyping of dozens of human pathogens—including SARS-CoV-2—at attomolar sensitivity with dramatically reduced reagent costs and scalable throughput. [2020]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. A low-cost serum RNA sequencing protocol that combines SISPA with CRISPR-Cas9–based DASH host depletion enables highly sensitive, untargeted pathogen detection on Oxford Nanopore at PCR-range sensitivity, outperforming commercial host-depletion methods in both cost and performance. [2026]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. A comprehensive review of advances in genetically engineered bacteriophages over the past decade, detailing engineering methods (recombineering, BRED, in vivo recombineering, CRISPR-Cas), applications in pathogen control, detection, drug delivery, vaccines, and phage-derived antimicrobials, while highlighting regulatory, safety, and translational challenges and future directions. [2016]

9QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

4. This review provides a comprehensive overview of CRISPR/Cas-based nucleic acid detection technologies for diagnosing animal infectious diseases, detailing the Cas9/Cas12/Cas13 platforms, pre-amplification and amplification-free strategies, signal readouts (colorimetric, fluorescence, and electrical), readout devices and microfluidic integrations, summarizing bacterial, viral, and parasitic applications in animals, comparing performance with conventional methods, and discussing current challenges... [2025]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

5. Multiplexed CRISPR-Cas13–based diagnostics (CARMEN) are optimized and validated for high-throughput detection of 23 pathogens across three panels (BBP1–BBP3), showing improved sensitivity over RT-qPCR in synthetic and clinical samples and enabling scalable pathogen surveillance. [2025]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

In the provided evidence, Cas12/Cas13 more directly “create” the detectable signal via collateral-cleavage reporters, whereas Cas9 in the showcased pipeline primarily reshapes the sample to enable downstream sequencing—so “Cas identity” alone doesn’t determine field readout; the assay workflow architecture does.

Keep Exploring

Which animal-pathogen CRISPR assays in the provided dataset use direct Cas9 detection (no sequencing) with explicit reporter readouts, and how do their LOD/specificity compare to Cas12/Cas13 collateral assays?

How do sample-prep choices (denaturation, RNaseH, amplification type) shift effective readout sensitivity for Cas12 vs Cas13 in serum/field matrices, based only on the studies included in the dataset?

Hypothesis Graveyard

Cas9 can be assumed to behave like Cas12/Cas13 with similar fluorescence/LFA readouts; this is not supported by the provided Cas9 evidence, which instead shows sequencing downstream after DASH depletion.

Cas13 multiplexing (CARMEN) implies universal feasibility of same readout modality for all animal pathogens; this overgeneralizes beyond the provided pathogen set and beyond deployment-specific constraints.

Potential Experiments

Build a workflow taxonomy experiment: implement the same pathogen targets in three parallel CRISPR workflows (Cas9-depletion+sequencing vs Cas12 collateral+LFB vs Cas13 collateral+fluorescence) using identical sample matrices and quantify (i) time-to-answer, (ii) false positives via off-target/cross-reactivity panels, (iii) limit of detection in inhibition-spiked samples. (Goal: isolate architecture effects.)

Test crRNA coverage sensitivity: for a given pathogen family, vary sequence divergence in synthetic targets and measure how LFA/fluorescence call rates decay for Cas12/Cas13 collateral assays, then compare whether Cas9-based depletion+sequencing maintains detection as divergence increases (because sequencing can recover novel sequences).

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may under-map Cas9 to LFA/colorimetric readouts because the provided Cas9 evidence (DASH) explicitly routes final detection through sequencing rather than direct reporter formats.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Bioinformatics claims and pipelines

See claims tied to computational experiments, including reported metrics, parameters, and source provenance for reproducibility checks.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Readout modalities for Cas9 vs Cas12 vs Cas13 in animal-pathogen CRISPR diagnostics

Cas9 vs Cas12 vs Cas13: what drives the signal (readout mechanism)

Modality “coverage” (binary, based on what’s explicitly in the provided papers)

Skeptical interpretation & known blind spots

Top Data Sources Export MCP

2. A low-cost serum RNA sequencing protocol that combines SISPA with CRISPR-Cas9–based DASH host depletion enables highly sensitive, untargeted pathogen detection on Oxford Nanopore at PCR-range sensitivity, outperforming commercial host-depletion methods in both cost and performance. [2026]

5. Multiplexed CRISPR-Cas13–based diagnostics (CARMEN) are optimized and validated for high-throughput detection of 23 pathogens across three panels (BBP1–BBP3), showing improved sensitivity over RT-qPCR in synthetic and clinical samples and enabling scalable pathogen surveillance. [2025]

7. A comprehensive review of HAV and HEV as food- and waterborne pathogens, summarizing transmission routes, food matrices involved, and the current detection methods and standardization status across diverse foods. [2023]

Ask a Follow-Up

Key Insight

Keep Exploring

Which animal-pathogen CRISPR assays in the provided dataset use direct Cas9 detection (no sequencing) with explicit reporter readouts, and how do their LOD/specificity compare to Cas12/Cas13 collateral assays?

How do sample-prep choices (denaturation, RNaseH, amplification type) shift effective readout sensitivity for Cas12 vs Cas13 in serum/field matrices, based only on the studies included in the dataset?

Hypothesis Graveyard

Cas9 can be assumed to behave like Cas12/Cas13 with similar fluorescence/LFA readouts; this is not supported by the provided Cas9 evidence, which instead shows sequencing downstream after DASH depletion.

Cas13 multiplexing (CARMEN) implies universal feasibility of same readout modality for all animal pathogens; this overgeneralizes beyond the provided pathogen set and beyond deployment-specific constraints.

Potential Experiments

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may under-map Cas9 to LFA/colorimetric readouts because the provided Cas9 evidence (DASH) explicitly routes final detection through sequencing rather than direct reporter formats.

Stay current without chasing every paper.

My BGPT

Trending

Bioinformatics claims and pipelines

See claims tied to computational experiments, including reported metrics, parameters, and source provenance for reproducibility checks.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Readout modalities for Cas9 vs Cas12 vs Cas13 in animal-pathogen CRISPR diagnostics

Cas9 vs Cas12 vs Cas13: what drives the signal (readout mechanism)

Modality “coverage” (binary, based on what’s explicitly in the provided papers)

Skeptical interpretation & known blind spots

Top Data Sources ExportMCP

2. A low-cost serum RNA sequencing protocol that combines SISPA with CRISPR-Cas9–based DASH host depletion enables highly sensitive, untargeted pathogen detection on Oxford Nanopore at PCR-range sensitivity, outperforming commercial host-depletion methods in both cost and performance. [2026]

5. Multiplexed CRISPR-Cas13–based diagnostics (CARMEN) are optimized and validated for high-throughput detection of 23 pathogens across three panels (BBP1–BBP3), showing improved sensitivity over RT-qPCR in synthetic and clinical samples and enabling scalable pathogen surveillance. [2025]

7. A comprehensive review of HAV and HEV as food- and waterborne pathogens, summarizing transmission routes, food matrices involved, and the current detection methods and standardization status across diverse foods. [2023]

Ask a Follow-Up

Key Insight

Keep Exploring

Which animal-pathogen CRISPR assays in the provided dataset use direct Cas9 detection (no sequencing) with explicit reporter readouts, and how do their LOD/specificity compare to Cas12/Cas13 collateral assays?

How do sample-prep choices (denaturation, RNaseH, amplification type) shift effective readout sensitivity for Cas12 vs Cas13 in serum/field matrices, based only on the studies included in the dataset?

Hypothesis Graveyard

Cas9 can be assumed to behave like Cas12/Cas13 with similar fluorescence/LFA readouts; this is not supported by the provided Cas9 evidence, which instead shows sequencing downstream after DASH depletion.

Cas13 multiplexing (CARMEN) implies universal feasibility of same readout modality for all animal pathogens; this overgeneralizes beyond the provided pathogen set and beyond deployment-specific constraints.

Potential Experiments

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may under-map Cas9 to LFA/colorimetric readouts because the provided Cas9 evidence (DASH) explicitly routes final detection through sequencing rather than direct reporter formats.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP